Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Celebrex Educational Campaign Or Name Change Expected By End Of May

Executive Summary

A decision on instituting a name change or educational campaign for Searle/Pfizer's Celebrex is expected by the end of May.

You may also be interested in...



Celebrex Name Keeps Drug Off Minnesota Health-System Formulary

The potential for Searle/Pfizer's arthritis therapy Celebrex to be confused with other products is keeping the drug off the formulary of Minneapolis-based Fairview Health Services, a hospital pharmacy director told a National Coalition on Health Care medical errors conference Feb. 22 in Washington, D.C.

Celebrex Name Keeps Drug Off Minnesota Health-System Formulary

The potential for Searle/Pfizer's arthritis therapy Celebrex to be confused with other products is keeping the drug off the formulary of Minneapolis-based Fairview Health Services, a hospital pharmacy director told a National Coalition on Health Care medical errors conference Feb. 22 in Washington, D.C.

Vioxx Strategy Aims To Switch Patients Up From OTC To Rx Market

Merck is looking to move patients out of the over-the-counter analgesic market to the prescription COX-2 inhibitor Vioxx, Merck Human Health-The Americas President David Anstice said at Merck's annual business briefing Dec. 9 in Whitehouse Station, N.J.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS034113

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel